-
Three top-class smaller biotechnology companiesOpinion Three smaller biotechnology companies with big potential, picked by Geoffrey Hsu, managing partner at OrbiMed and portfolio manager of the Biotech Growth Trust.
Opinion -
Diamonds have lost their lustre – are they worth buying?The diamond industry is at a crossroads, with laboratory-grown diamonds further diminishing the gemstone's appeal. Are they no longer an investor's best friend?
-
The extraordinary rise of Sea Limited, Asia's online marketplaceAsian online shopping company Sea Limited is well placed to recover from recent disasters. Is it time to buy its shares?
-
Is the whisky market waking up after the Covid binge?Rare whisky boomed during the pandemic, but higher interest rates brought a slump. With trophy bottles holding firm, could the market be waking up?
-
The nuclear industry is set to melt up – here’s what to buyOpinion Some of the nuclear industry’s first-rate firms are being ditched by distressed sellers. Nick Lawson explains why you should snap them up
Opinion -
How prediction markets harness the wisdom of crowdsPrediction markets have an enviable record of foresight when compared with experts and polling companies. But they can also be dangerous for the unwary
-
MoneyWeek Wealth Summit 2026: investing in the age of changeLearn from top investors at the MoneyWeek Wealth Summit 2026 on 6 November. Here's a full rundown of the guests and subjects.
-
What’s happening with UK house prices? Latest property forecasts for 2026The UK housing market continues to struggle as higher mortgage rates brought on by the Middle East conflict pinch buyers.
-
Consumer brands are in the bargain bin – how to investPowerful consumer brands can deliver long-term value, but it's not a one-way bet. Here are the products offering the best value for shareholders
